Headline Roundup • October 1st, 2020

COVID-19 Vaccine Speculation Persists; Healthcare Firms Outline Careful Development

Coronavirus Vaccine,Healthcare,Life During Covid-19,Safety And Sanity During COVID-19,Coronavirus

Summary from the AllSides News Team

CEOs of Moderna and Pfizer, two healthcare firms working to develop COVID-19 vaccines, stated this week that their companies wouldn't rush development or compromise safety protocols due to political agendas or the 2020 presidential election. Meanwhile, vaccine trials and various experiments and studies persist, and speculation continues about how the treatment could potentially impact the White House race, and whether or not it'll be safe enough for the general public to use. Some conducted studies into public perception of the vaccine and whether or not people say they'll take it when made available. Some coverage from left-rated sources mentioned reports and analysis that suggest daily restrictions will continue after the vaccine is distributed. Some reports from right-rated outlets concentrated on analysis and experiments that suggest vaccine development might be quicker than expected.

Featured Coverage of this Story

An experimental antibody treatment reduced viral load in some COVID-19 patients. That may also be a positive sign for vaccines

MarketWatch

See rating details

An experimental antibody treatment reduced viral load in some COVID-19 patients. That may also be a positive sign for vaccines

MarketWatch

News

Promising new clinical data for an experimental COVID-19 treatment hints at a secondary but possibly more important takeaway for investors: if this neutralizing antibody treatment works in coronavirus patients, so will the vaccines that are in development.

Regeneron Pharmaceuticals Inc. REGN, +1.49% on Tuesday shared preliminary data from a Phase 1/2/3 clinical trial for REGN-COV2, finding that the investigational therapy reduced viral load and made symptoms go away sooner in some non-hospitalized patients with mild or moderate cases of COVID-19. It was most effective in patients with higher viral loads...

Open on MarketWatch

Coronavirus vaccine trial participants report day-long exhaustion, fever and headaches — but say it’s worth it

CNBC

See rating details

News

Luke Hutchison woke up in the middle of the night with chills and a fever after taking the Covid-19 booster shot in Moderna’s vaccine trial. Another coronavirus vaccine trial participant, testing Pfizer’s candidate, similarly woke up with chills, shaking so hard he cracked a tooth after taking the second dose.

High fever, body aches, bad headaches and exhaustion are just some of the symptoms five participants in two of the leading coronavirus vaccine trials say they felt after receiving the shots.

In interviews, all five participants — three in Moderna’s...

Open on CNBC

Covid-19 vaccine alone won't defeat spread of virus, report warns

The Guardian

See rating details

News

A successful vaccine for Covid-19 will not conquer the spread of the virus alone, with restrictions on daily life likely to continue for some time, a team of experts have said.

Hundreds of teams of researchers around the world are working to produce a vaccine against the coronavirus, with 11 currently in phase three human trials. The UK government has reserved access to six potential vaccines and has raised hopes that a vaccine could be on the cards by spring next year.

A report from a multidisciplinary group convened by...

Open on The Guardian

More headline roundups